Susquehanna International Group
NVIV

Susquehanna International Group’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Susquehanna International Group’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-3
Closed -$377K – 9443
2016
Q2 		$377K Sell
3
-1
-25% -$118K ﹤0.01% 6596
2016
Q1 		$553K Buy
4
+2
+100% +$215K ﹤0.01% 6217
2015
Q4 		$212K Hold
2
– – ﹤0.01% 8329
2015
Q3 		$257K Buy
+2
New +$467K ﹤0.01% 8299

Other funds holding NVIV

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Susquehanna International Group's NVIV Position: Q1 2020 in Review

Susquehanna International Group sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2020, closing a stake of 57 shares — an estimated $10K sold.

Susquehanna International Group first reported a position in NVIV in Q2 2015 and held it in 11 quarters. The position peaked at $738K in Q3 2015. 10 funds tracked by Wall St. Rank hold NVIV as of Q1 2020.

  • Susquehanna International Group reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2020 after selling out during the quarter.
  • Susquehanna International Group sold 57 InVivo Therapeutics Holdings Corp shares in Q1 2020, an estimated $10K.
  • Susquehanna International Group first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 11 quarters.
  • Susquehanna International Group's InVivo Therapeutics Holdings Corp position peaked at $738K in Q3 2015.
  • 10 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2020.

Based on Susquehanna International Group's 13F filing for Q1 2020, filed 15 May 2020.